Upcoming Medical Conferences in London

3rd Scientific Workshop on Tumour Microenvironment in the Haematological Malignancies and its Therapeutic Targeting is organized by European School of Haematology (ESH) and will be held from Feb 24 - 26, 2019 at Francis Crick Institute, London, England, United Kingdom. Course Description: This workshop offers highest level science on the nature of the normal and malignant haemopoietic stem cell niche. It also aims to present strategies to target haematological cancers in their tumour microenvironment, thereby combining basic research efforts with possible clinical applications. It is designed to promote scientific interaction between participants from all over the world, involving junior and senior biologists and clinicians working in both the academic and industrial settings. Course Objectives: • Define the currently known complexities of the normal and malignant haematopoietic stem cell niche. • Define the complexities of metabolic changes in the bone marrow microenvironment in health and disease. • Define the effects of inflammatory processes on the bone marrow microenvironment in health and disease. • Define the interaction of haematological cancer cells with their microenvironment and methods to visualize and mimic these. • Define strategies to target the malignant haematopoietic stem cell niche to augment existing therapies.

euroPLX 69 London is organized by RauCon business development and will be held from Feb 25 - 26, 2019 at Sofitel London Heathrow Hotel, London, England, United Kingdom. Additional details will be posted as soon as they are available.

CAR-TCR Summit Europe is organized by Hanson Wade and will be held from Feb 25 - 27, 2019 at Hotel Novotel London West, London, England, United Kingdom. Who Attends: Academic Institutions, Biotechs, Large Pharma. The CAR-TCR Summit Europe is your opportunity to join the expert CAR and TCR pioneers to learn about never-before-seen clinical updates and novel technology to improve solid tumour targeting, advance allogeneic therapy development and automate manufacturing processes to reduce the cost of goods.  If you are looking to initiate clinical trials in Europe, join us to navigate the complex regulations and reimbursement landscape to understand and overcome market access challenges.  And if you are looking to drive progress in scientific discovery, join us as we discuss novel breakthroughs with innovations with gamma delta and NKT cells, innovative antigen screening platforms and genetic engineering strategies to create, translate and develop the next generation of CAR and TCR therapies. Encapsulating this excitement, the CAR-TCR Summit Europe is providing you with the platform to learn from the experience of industry pioneers, hear novel clinical updates and network with key opinion leaders to takeaway valuable lessons learnt to improve upon your CAR-TCR pipeline. Key topics to be addressed: • Novel technologies to create the next generation of CAR and TCR therapies exploring Medigene ’ s genetically engineered t cells, Fate ’ s dual-targeted TCR and the progression of allogeneic development with updates from Celyad and Cellectis • Improve solid tumour targeting with antigen identification strategies from Immatics and cutting edge engineering from Marker Therapeutics to target novel antigens and reduce off-tumour toxicity • Automate and streamline manufacturing processes with strategies from UCL which utilize an automated high-throughput microbioreactor system to ensure process consistency • Navigate the European regulatory challenges to initiate trials across multiple countries with advice and guidance from the EMA • Pricing strategies to prepare for accessible reimbursements with insights shared from NICE and CEVR on the value of these potentially curative therapies Time: 08:00 to 17:00 Prices: Conference + Workshop Day: GBP 2498.0, Conference Only: GBP 1699.0, Conference + Workshop Day (Early Bird ends Friday 25th January, 2019): GBP 2398.0, Conference Only (Early Bird ends Friday 25th January, 2019): GBP 1599.0 Speakers: Dale Ludwig, Chief Scientific Officer, Actinium Pharmaceuticals, Barbra Sasu, Chief Scientific Officer, Allogene Therapeutics, Christian Itin, Chief Executive Officer, Autolus, Vicki Coutinho, Senior Director, Regulatory Affairs, Autolus, Jie Jia, Vice President, Strategic Alliances CARsgen Therapeutics, Zonghai Li , Chief Executive Officer, CARsgen Therapeutics, Tony Ho Executive Vice President, Head of Research and Development, CRISPR Therapeutics, Stefanos Theoharis, Senior Vice President, Corporate Development and Partnering, Cell Medica, Stephane Depil, Senior Vice President Research and Development and Chief Medical, Cellectis, David Gilham, Vice President, Research and Development, Celyad, Detlev Parow Head of Department of Medicines, Therapeutic Appliances and Remedies Product and Billing Management Division, DAK-Gesundheit, Bob Valamehr Chief Development Officer and Vice President Cancer Immunotherapy, Fate Therapeutics, Cedrik Britten, Head of Oncology Cell Therapy Research Unit, GSK, Harpreet Singh, Chief Executive Officer, Immatics US, Will Singleterry Associate Director, Business Development, Isoplexis, Marc Kamp Director CAR-T Product Distribution and Supplier Quality Management, Kite Pharma, John Maher, Chief Scientific Officer, Leucid Bio, Juan Vera, Chief Development Officer, Marker Therapeutics, Peter L. Hoang, President and Chief Executive Officer, Marker Therapeutics, Dolores Schendel, Chief Executive Officer and Chief Scientific Officer, Medigene, Kai Pinkernell, Chief Medical Officer and Chief Development Officer, Medigene, James McBlane Preclinical Assessor, MHRA and Member, Committee for Advanced Therapies (CAT), EMA, Katharina Winnemöller, Marketing Manager for Clinical Cell Processing and T Cell Applications, Miltenyi Biotec, Pilar Pinilla Dominguez Senior Scientific Adviser, NICE, Therese Choquette Analytical Project Leader, Cell and Gne Therapy Development and Manufacturing, Novartis, Francesco Marincola, Chief Scientific Officer, Refuge Biotech, Jim Freeth Co-managing Director, Retrogenix, Véronique Blanc Immuno-Oncology Program Director, Servier, Michael Leek, Chief Executive Officer, TC Biopharm, Alfonso Quintás Cardama, Chief Medical Officer, TCR2 Therapeutics, Dan Ollendorf, Director Value Measurement and Global Health Initiatives, Tufts University Center for the Evaluation of Value and Risk in Health, CEVR, Qasim Rafiq, Senior Lecturer in Bioprocessing of Regenerative, Cellular and Gene Therapy, UCL, Miguel Forte Chief Executive Officer, Zelluna Immunotherapy, Laurence Cooper, Chief Executive Officer, Ziopharm Oncology, Jens Hasskarl, Senior Director, Research Development, Clinical and Medical, Celgene Corporation, Maureen Graham, Managing Director, Diamond Pharma Services, Andreas Göbel Executive and Technology Lead, Hypertrust Patient Data Care, Kai Wilkens, Senior Director Europe ACD, Bio-Techne

2nd Global Non-Alcoholic Steatohepatitis (NASH) Congress is organized by Global Engage Ltd and will be held from Feb 25 - 26, 2019 at London Heathrow Marriott Hotel, London, England, United Kingdom. Synopsis: • +40 presentations from industry and academic leaders • +7 hours of dedicated networking time • Expert-led roundtables and interactive panels Attracting experts working in all areas of nonalcoholic steatohepatitis, the conference will examine the latest research and development in pathogenesis, diagnosis, and treatment of the disease. An increasing number of people are being diagnosed with the nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) each year, and the primary method of treatment is weight loss. With no approved medicines on the market, the drug development race is intensifying. The pathogenesis of NASH is still not fully understood, and definitive diagnostic methods are invasive, so development has been slow. There are, however, promising developments in research that will hopefully bolster drug development and other methods of treatment. Examples of such developments include improved in vivo liver models, non-invasive diagnostic biomarkers and a better understanding of the disease’s mechanisms. This year’s congress will focus on these exciting advancements, as well as on the challenges of preclinical and clinical research in NASH. There will also be a session on business development/regulation and a showcase of the most promising therapeutics in development. Additional details will be posted as soon as they are available.

ENT Anaesthesia - 2 Day Seminar is organized by The Association of Anaesthetists of Great Britain and Ireland (AAGBI) and will be held from Feb 25 - 26, 2019 at Association of Anaesthetists of Great Britain and Ireland, London, England, United Kingdom.​ Conference Description: This conference includes all the essential aspects of issues involved in anaesthesia patients for ENT surgery. This will enable delegates to refresh their knowledge on current trends in anaesthesia for ENT surgery and keep you updated. Additional details will be posted as soon as they are available.

Recent Developments in AI and Digital Health 2019 is organized by The Royal Society of Medicine (RSM) and will be held on Feb 26, 2019 at The Royal Society of Medicine, London, England, United Kingdom. Artificial Intelligence (AI) is heralded as a disruptive technology that will revolutionize many industries including health and social care. But as AI systems get better at sorting data and making predictions, the role of this technology alongside existing healthcare professionals is unclear.   This event will feature academics, doctors, and entrepreneurs at the forefront of AI and healthcare, and will include a debate on whether AI is poised to deliver the improved patient experiences and outcomes that many are suggesting.    Delegates will have the opportunity to hear from AI thought leaders such as Dr. Matt Fenech, AI consultant at the Future Advocacy think-tank on the ethical regulatory perspectives on AI in healthcare, and Dr. Hugh Harvey, radiologist and Medical Director of Kheiron Medical Technologies, who will discuss how deep learning could transform NHS breast screening.   This event is for anyone who is keen to understand the myriad of ways AI is being applied in healthcare, whilst understanding the ethical implications of integrating deep learning algorithms and neural networks into our healthcare systems.  Topics : • A comprehensive overview of the ethical and regulatory implications of AI and healthcare  • Showcase exciting cases of AI in healthcare including diagnosis, screening and drug development   • Explore whether AI in healthcare can really deliver improved patient outcomes and better patient experiences Additional details will be posted as soon as they are available.

Masterclass in Head & Neck Symptoms 2019 is organized by Allergy Academy and will be held on Feb 26, 2019 at Science Gallery London, London, England, United Kingdom. The target audience for this medical event is General Practitioners, GP Registrars, Allergists, Paediatricians, General Practitioners, Nurses, Opticians. Course Description: The allergy academy is delighted to announce our first day aimed at ophthalmic and ENT presentations of allergic disease! This half-day training day is targeted at a broad range of specialties including general practice, allergists, pediatricians and surgical specialties, and promises to be filled with useful clinical advice and scientific evidence to guide your practice. This course is available either as a whole day event or as either a morning or an afternoon half day event if delegates are not available for the whole day. Aims: • To cover the clinical presentations of allergic eyes diseases and upper airway obstruction • To understand the approach to managing eczema in the orbital region • To understand the use and potential applications of corneal and nasal provocation testing • To review the current use and applications of immunotherapy for allergic rhinoconjunctivitis Additional details will be posted as soon as they are available.

Menopause in the Workplace is organized by The Royal Society of Medicine (RSM) and will be held on Feb 26, 2019 at The Royal Society of Medicine, London, England, United Kingdom. One in four women currently going through menopause have considered leaving work due to their symptoms. Some studies also suggest that some work environments may make menopause symptoms worse. Despite this, the majority of women are unwilling to disclose menopause related health problems to their line managers due to the taboo surrounding the subject and the fact that there is a lack of interest in addressing the subject in many workplaces. This event addresses the issues working women face throughout menopause, with consideration to the influence employers have on women's economic participation and the potential impact of the secrecy surrounding menopause has on the workplace and wider labour market. Topics : •  How women experiencing menopause can be better supported at work •  Measuring the economic costs of menopause •  Evidence gaps relating to the menopause transition and the workplace Additional details will be posted as soon as they are available.

IPC in adult and paediatric critical care is organized by Healthcare Infection Society (HIS) and will be held on Feb 27, 2019 at Mary Ward House Conference Centre, London, England, United Kingdom.. Attendance at Trainee Education Days is FREE for HIS Trainee Members, however a refundable deposit of £50 is required to secure your place. Additional details will be posted as soon as they are available.

Launch of Taskforce report: CVD: Diet, Nutrition and Emerging Risk Factors is organized by British Nutrition Foundation (BNF) and will be held on Feb 27, 2019 at Royal Society of Chemistry, London, England, United Kingdom. Course Description: Cardiovascular disease (CVD) is a major cause of early death and disability across the world. The major markers of risk are well known, but such markers do not account for all cardiovascular risk. This new comprehensive book examines the evidence for emerging and novel risk factors, and their relationship with diet and nutrition. Cardiovascular Disease: Diet, Nutrition and Emerging Risk Factors covers everything from epidemiology to genetic factors, to inflammation and much more – offering invaluable advice on reducing risk factors and preventing CVD, and: ○ Authoritatively reports on the link between emerging aspects of diet, lifestyle and cardiovascular disease risk ○ Focuses on novel risk factors of CVD, including the human gut microbiome and fetal and childhood origins, and how it can be prevented ○ Features recommendations for interventions and future research ○ Includes references, commonly asked questions that summarise the take-home messages, and an online glossary Additional details will be posted as soon as they are available.